Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-645M | $-582M | $-371M | -30.3% | -100.0% | 58.8% |
| 2024 | $35M | $-447M | $-366M | $-145M | -19.0% | -90.5% | 138.4% |
| 2023 | $370M | $-203M | $-154M | $-272M | -8.2% | 84762.4% | -76.4% |
| 2022 | $0M | $-649M | $-650M | $-533M | -34.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0.44 | 370 | 35 | 0 |
| Operating Revenue | - | 0.44 | 370 | 35 | 0 |
| Cost Of Revenue | - | 110.25 | 130.25 | 120.67 | 213.48 |
| Gross Profit | - | -109.81 | 239.75 | -85.67 | -213.48 |
| Operating Expense | - | 563.35 | 462.29 | 380.90 | 451.09 |
| Research And Development | - | 461.64 | 387.33 | 310.24 | 381.06 |
| Selling General And Administration | - | 102.46 | 76.16 | 72.98 | 73.54 |
| Total Expenses | - | 673.60 | 592.54 | 501.57 | 664.57 |
| Operating Income | - | -673.16 | -222.54 | -466.57 | -664.57 |
| Total Operating Income As Reported | - | -673.16 | -222.54 | -466.57 | -664.57 |
| EBITDA | - | -648.99 | -202.70 | -447.31 | -645.09 |
| Normalized EBITDA | - | -648.99 | -202.70 | -447.31 | -645.09 |
| EBIT | - | -673.16 | -222.54 | -466.57 | -664.57 |
| Other Non Operating Income Expenses | - | 22.66 | 71.82 | 103.90 | 86.61 |
| Other Income Expense | - | 22.66 | 71.82 | 103.90 | 86.61 |
| Pretax Income | - | -650.50 | -150.72 | -362.66 | -577.96 |
| Tax Provision | - | -0.32 | 2.89 | 3.59 | 3.63 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Net Income From Continuing And Discontinued Operation | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Net Income From Continuing Operation Net Minority Interest | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Net Income | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Net Income Common Stockholders | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Net Income Including Noncontrolling Interests | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Normalized Income | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Diluted NI Availto Com Stockholders | - | -650.17 | -153.61 | -366.25 | -581.60 |
| Basic Average Shares | - | 77.75 | 79.22 | 84.36 | 89.93 |
| Diluted Average Shares | - | 77.75 | 79.22 | 84.36 | 89.93 |
| Reconciled Depreciation | - | 24.17 | 19.84 | 19.26 | 19.48 |
| Reconciled Cost Of Revenue | - | 110.25 | 130.25 | 120.67 | 213.48 |
| General And Administrative Expense | - | 102.46 | 76.16 | 72.98 | 73.54 |
| Other Gand A | - | 102.46 | 76.16 | 72.98 | 73.54 |
| Other Operating Expenses | - | -0.76 | -1.21 | -2.31 | -3.51 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics AGthis co. | CRSP | $5.5B | - | 2.86 | -30.3% | - |
| Rhythm Pharmaceuticals, Inc. | RYTM | $6.0B | - | 22.25 | -74.8% | - |
| PACS Group, Inc. | PACS | $5.9B | 30.96 | 6.26 | 20.2% | 24.98 |
| Mirum Pharmaceuticals, Inc. | MIRM | $5.6B | -241.41 | 17.92 | -7.4% | 329.12 |
| Cogent Biosciences, Inc. | COGT | $5.6B |
| - |
| - |
| - |
| - |
| - |
| - |
| -17.03 |
| 10.24 |
| -60.1% |
| -17.21 |
| Liquidia Corporation | LQDA | $5.6B | -80.69 | 124.29 | -154.0% | -128.84 |
| Scholar Rock Holding Corporation | SRRK | $5.4B | - | 22.13 | -154.0% | - |
| Xenon Pharmaceuticals Inc. | XENE | $5.1B | -14.81 | 8.80 | -59.5% | -13.31 |
| CG Oncology, Inc. | CGON | $4.9B | -30.73 | 6.57 | -21.4% | -26.00 |
| Peer Median | - | -23.88 | 14.08 | -59.8% | -15.26 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Nov has averaged the highest return (+11.5%); Mar the lowest (-13.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.7%Negative MonthJan 2026: -4.73% | +20.4%Positive MonthFeb 2026: +20.38% | -20.9%Negative MonthMar 2026: -20.90% | +10.0%Positive MonthApr 2026: +10.03% | +7.3%Positive MonthMay 2026: +7.34% | -2.9%Negative MonthJun 2026: -2.92% | -12.0%Negative MonthJul 2026: -12.01% | +24.6%*Positive MonthAug 2026: +24.63% | — | — | — | — |
| 2025 | +5.7%Positive MonthJan 2025: +5.67% | +5.6%Positive MonthFeb 2025: +5.60% | -22.5%Negative MonthMar 2025: -22.52% | +13.6%Positive MonthApr 2025: +13.64% | -6.2%Negative MonthMay 2025: -6.15% | +34.0%Positive MonthJun 2025: +34.03% | +15.7%Positive MonthJul 2025: +15.67% | -7.9%Negative MonthAug 2025: -7.87% | +25.0%Positive MonthSep 2025: +25.04% | -1.3%Neutral MonthOct 2025: -1.27% | -16.4%Negative MonthNov 2025: -16.44% | -1.9%Neutral MonthDec 2025: -1.93% |
| 2024 | +0.6%Neutral MonthJan 2024: +0.56% | +33.8%Positive MonthFeb 2024: +33.79% | -19.1%Negative MonthMar 2024: -19.07% | -22.3%Negative MonthApr 2024: -22.26% | +1.4%Neutral MonthMay 2024: +1.42% | +0.5%Neutral MonthJun 2024: +0.50% | +6.1%Positive MonthJul 2024: +6.07% | -16.7%Negative MonthAug 2024: -16.70% | -1.6%Neutral MonthSep 2024: -1.55% | -1.3%Neutral MonthOct 2024: -1.26% | +10.3%Positive MonthNov 2024: +10.30% | -23.1%Negative MonthDec 2024: -23.08% |
| 2023 | +25.5%Positive MonthJan 2023: +25.51% | -3.3%Negative MonthFeb 2023: -3.33% | -8.3%Negative MonthMar 2023: -8.29% | +8.2%Positive MonthApr 2023: +8.20% | +30.9%Positive MonthMay 2023: +30.85% | -12.3%Negative MonthJun 2023: -12.34% | +2.1%Positive MonthJul 2023: +2.12% | -12.8%Negative MonthAug 2023: -12.77% | -9.2%Negative MonthSep 2023: -9.24% | -14.2%Negative MonthOct 2023: -14.23% | +71.4%Positive MonthNov 2023: +71.41% | -6.2%Negative MonthDec 2023: -6.19% |
| 2022 | -15.9%Negative MonthJan 2022: -15.87% | -3.7%Negative MonthFeb 2022: -3.73% | +2.3%Positive MonthMar 2022: +2.28% | -20.9%Negative MonthApr 2022: -20.95% | +17.0%Positive MonthMay 2022: +16.99% | +4.7%Positive MonthJun 2022: +4.69% | +23.4%Positive MonthJul 2022: +23.42% | -13.2%Negative MonthAug 2022: -13.21% | +0.4%Neutral MonthSep 2022: +0.40% | -19.9%Negative MonthOct 2022: -19.91% | +4.7%Positive MonthNov 2022: +4.68% | -25.8%Negative MonthDec 2022: -25.81% |
| 2021 | — | — | — | — | -10.0%Negative MonthMay 2021: -9.97% | +37.0%Positive MonthJun 2021: +36.99% | -25.2%Negative MonthJul 2021: -25.25% | +3.2%Positive MonthAug 2021: +3.25% | -10.4%Negative MonthSep 2021: -10.42% | -18.4%Negative MonthOct 2021: -18.40% | -12.5%Negative MonthNov 2021: -12.52% | -5.2%Negative MonthDec 2021: -5.16% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
